Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
The global Blinatumomab market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Blinatumomab volume and value at global level, regional level and company level. From a global perspective, this report represents overall Blinatumomab market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Blinatumomab in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Blinatumomab manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Amgen
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Prefilled
Non-prefilled
Segment by Application
Hospital
Pharmacy
Summary:
Get latest Market Research Reports on Blinatumomab. Industry analysis & Market Report on Blinatumomab is a syndicated market report, published as Global Blinatumomab Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Blinatumomab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.